Foscarnet decreases HIV-1 plasma load

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 1, 1998, Pages 46-50

  Devianne Garrigue, Isabelle ^a   Pellegrin, Isabelle ^a   Denisi, Rocco ^a   Dupon, Michel ^a   Ragnaud, Jean Marie ^a   Barbeau, Pascal ^a   Breilh, Dominique ^a   Leng, Bernard ^a   Fleury, Herve J A ^a   Pellegrin, Jean Luc ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

AIDS; CMV disease; Foscarnet; HIV 1 RNA; Kaposi's Sarcoma

Indexed keywords

FOSCARNET;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CHOLECYSTITIS; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; TREATMENT PLANNING; VARICELLA ZOSTER VIRUS; VIREMIA; VIRUS REPLICATION;

CHIRON; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HERPES; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032079437     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199805010-00007     Document Type: Article

References (15)

1. Koshida R, Vrang L, Gilljam G, Harmenberg J, Ober B, Wahren B. Inhibition of human immunodeficiency virus in vitro by combinations of 3′-azido-3′deoxythymidine and foscarnet. Antimicrob Agents Chemother 1989;33:778-80.
2. Eriksson BF, Schinazi RF. Combinations of 3′-azido-3′-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1989;33: 663-9.
3. Morfeldt L, Torssander J. Long term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994;26:749-52.
4. Studies of Ocular Complications of AIDS Research Group, in collaboration with AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
5. Studies of Ocular Complication of AIDS Research Group, in collaboration with AIDS Clinical Group. Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p 24 antigen in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995;172:613-21.
6. Kaiser L, Perrin L, Hirschel B, et al. Foscarnet decreases human immunodeficiency virus RNA. J Infect Dis 1995;172:225-7.
7. Balfour H, Fletcher C, Erice A, et al. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob Agents Chemother 1996; 40:2721-6.
8. Centres for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36(Suppl 1S):1S-15S.
9. Reddy MM, Grieco MH, McKinley GF, et al. Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. J Infect Dis 1992; 166:607-10.
10. Bergdahl S, Sonnerborg A, Larsson A, Strannegard O. Declining levels of HIV p24 antigen in serum during treatment with foscarnet. Lancet 1988;1:1052.
11. Segondy M, Montes B, Delmas B, Leclercq C, Janbon F, Reynes J. Changes in HIV-1 RNA plasma level in patients treated with foscarnet. J Acquir Immune Defic Syndr 1997;14:79-80.
12. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azido-thymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:185-91.
13. Yarchoan R, Thomas RV, Allain JP, et al. Phase I studies of 1′,3′-dideoxycytidine in severe human immunodeficiency virus infections as a single agent and alternating with zidovudine (AZT). Lancet 1988;I:76-81.
14. Jacobson MA, Crowe S, Levy J, et al. Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis 1988;158:862-5.
15. Fletcher CV, Collier AC, Rhombi FS, et al., Foscarnet for suppression of human immunodeficiency virus replication. Antimicrob Agents Chemother 1994;38:604-07.